Key words
endocrine disrupting chemicals - adrenal gland - corticosteroids - HPA axis - bisphenol A
Introduction
In times of the Anthropocene, increasing production and environmental release of
synthetic chemicals pose a significant challenge for ecological balance and a hazard
to human health. The planetary resilience for anthropogenic pollution in terms of
quantity and diversity of chemicals introduced and distributed is postulated to be
already reached [1]. By today, approximately
140 000 chemical substances have been registered, of which 5000 are extensively
produced and dispersed. Less than half have undergone adequate environmental risk
assessment, as testing has only become mandatory in recent decades, particularly in
high-income countries [2]
[3]. A relevant proportion of these substances
are able to interfere with cellular structures of endocrine organs and alter
endocrine pathways or homeostasis. Such endocrine-disrupting chemicals (EDCs) might
be defined as “exogenous substance(s) or mixture that (alter) function(s) of
the endocrine system and consequently (cause) adverse effects in an intact organism,
or its progeny, or (sub-)populations” [International Programme on Chemical
Safety (IPCS)] [4].
EDCs can be found in agricultural, industrial, domestic, and medical applications.
They have been or are used as herbicides or fungicides in food production
[e. g., dichlorodiphenyltrichloroethane (DDT), atrazine, glyphosate], as
plasticisers (e. g., phthalates, bisphenols), in personal-care products
(e. g., parabens, benzophenones) [5],
and in construction, furniture, and electrical applications as flame retardants
[e. g., polybrominated diphenyl ethers (PBDE)]. Ultimately, they are found
in children’s toys (e. g., phthalates, PBDE) [6] 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Dioxins
emerge as by-products of industrial combustion (e. g.,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)). Polychlorinated biphenyls
(PCBs) have been used in capacitors, while per- and polyfluorinated substances
(PFAS) serve in water-repellent textiles or in fire-fighting foams. Some heavy
metals, such as cadmium, copper, or mercury, increasingly mined and distributed,
count among the list of endocrine-disrupting substances. Micro- and nanoplastic
particles as products of physical and environmental degradation can serve as
hydrophobic absorbing surfaces for EDCs with whom they can enter organisms and cross
epithelial barriers [7]. The mentioned
substances rank among the most prominent disruptive agents, which, at the same time,
we encounter on a daily basis [8].
From their primary fields of application, these substances are released through
volatilization. By now, they have been distributed around the globe and found even
in remote regions, such as the Mount Everest [9] or the Mariana Trench [10].
Global transport of toxins via air and ocean currents, global (waste) trade and
supply chains make the distribution of potential hazardous chemicals a worldwide
problem [11]. For instance, ubiquitous
particulate matter (PM) delivers complex mixtures of air pollutants, such as nitric
or sulfur oxides, heavy metals, or polycyclic aromatic hydrocarbons, which are known
for an endocrine disruptive activity [12].
Despite ambitious political regulations, restricted chemicals can and will still be
found in recycled materials for a long time complicating their elimination from
environmental cycles [6]
[13].
In addition, some endocrine-disruptive agents are predisposed to biomagnification,
accumulation, and long-range transport. Their long half-lifes indicate only little
biodegradation and promote the enrichment in food chains and the environment [2]. For instance, if PBDEs were banned
immediately, they would still be detectable in landfills beyond 2080 [14]. Widespread PFAS, however, appear to be
highly resistant to environmental degradation allowing persistence for hundreds of
years after release. Their thermal and chemical stability contribute to accumulating
concentrations and ubiquitous exposure [15].
Finally, after incorporation via ingestion, inhalation or dermal uptake, EDCs can be
detected in human samples, such as serum, urine, milk, but also placental tissue
[16], seminal plasma [17], saliva [18], or amniotic fluid [19].
Individual levels might depend on lifestyle, profession, socioeconomic status [20], local environment, and political
regulations. Regional initiatives conduct systematic biomonitoring studies allowing
the analysis in different populations, age groups and countries (e. g.,
HBM4EU [21]). Nevertheless, all humans are
certainly continuously exposed to a complex mixture of low-dosed EDCs with different
structures and toxicokinetic properties [8].
The tremendous amount and variety of introduced chemicals requires precise regulation
and consideration of potential hazards for environmental balances and health of
wildlife and humans [2]. Meanwhile,
EDC-associated adverse outcomes resulted in ambitious regulation of substances, for
example, via continuous determination of tolerated intake doses (TDI). For instance,
just very recently the EFSA (European Food Safety Authority) proposed a TDI of
0.2 ng/kg body weight/day for bisphenol A (BPA) illustrating
the need for continuous research of potential health implications in order to
control exposure to hazardous substances [22].
Another milestone towards chemical safety is the Stockholm Convention on persistent
organic pollutants banning most toxic substances in 2004 [23]. However, substitutes for hazardous
endocrine disruptors, which are introduced in order to replace their precursor like
bisphenol F (BPF) instead of BPA or DINCH (1,2-cyclohexanedicarboxylic acid
diisononyl ester) replacing diethylhexyl phthalate (DEHP) are only superficially
characterized. Retrospective hazard identification after years of unlimited use and
release is a hazardous and unsustainable, yet common practice.
More and more epidemiological data show associations between EDCs and susceptibility
for metabolic diseases (e. g., insulin metabolism, obesity), reproductive
impairments (e. g., reduced fertility, preterm births, polycystic ovary
syndrome, or cryptorchidism), incidence of hormone-related cancers (e. g.,
breast and prostate cancer), but also neurocognitive and behavioural pathologies.
Evidence of disruption of the thyroid system (e. g., altered T3/TSH
levels, iodine uptake) is growing, as well as the potential impairment of
hypothalamic-pituitary axes [8]. Besides, EDCs
might be risk factors for foetal development. Crossing placental barriers, they
might contribute to an unfavourable environment in utero [24].
While preliminary data from observational studies indicate an association with
adrenal neoplasia [25]
[26], no causality between the exposome (sum of
environmental factors influencing human health) and the development of disorders of
the adrenal cortex, associated hormones and their circadian rhythmicity has been
described, yet. Data on the interaction of EDC and the adrenal gland are still
scarce compared to other endocrine glands, such as the thyroid. We therefore try to
shed light on this important aspect of endocrine physiology and pathophysiology.
The adrenal gland as toxicological target
The adrenal gland as toxicological target
The adrenal gland consists of the cortex and the medulla. Steroidogenesis in
adrenocortical cells is mediated by a cascade of enzymes. Cells of the subcapsular
zona glomerulosa (ZG) produce mineralocorticoids, maintaining
sodium/potassium homeostasis. Cells of the zona fasciculata (ZF) produce
glucocorticoids, especially cortisol, relevant for stress response, metabolic
homeostasis, and immune regulation. Cells of the reticular zone (ZR) produce
precursors of androgens, for example, dehydroepiandrosterone (sulfate) and
androstenedione. Feedback loops between limbic areas, the hypothalamic
paraventricular nucleus (PVN), pituitary and adrenal glands allow the maintenance of
precise steroid levels under physiological conditions [27].
Nevertheless, the exposure of the adrenal tissue to endocrine disruptive agents
cannot be quantified sufficiently in vivo [26]. Conventional biomonitoring of body fluids, for example urine, does not
allow to draw clear conclusions on adrenal concentrations of EDCs. However, the
adrenal cortex has several predisposing characteristics making it particularly
vulnerable to endocrine disruption [27]
[28].
The efficient blood circulation enables the adrenal gland to rapidly release its
products into the bloodstream, but, on the other hand, contributes to the constant
exposure to potential disruptive substances. Additionally, the lipophilic milieu due
to the high content of cholesterol esters in the adrenal cortex enables lipophilic
toxicants to accumulate and endure. The high density of receptors such as
high-density lipoprotein (HDL) and scavenger receptor class B type 1 (SRB1) for the
uptake of lipid precursors allow the storage and persistence of lipophilic
contaminants. For instance, flame-retardant PBDEs were shown to be effectively
absorbed after oral administration, retained in lipophilic tissue and enriched in
certain organs, such as the adrenal glands [29]
[30]. Additionally, derivatives
of the insecticide DDT were found to accumulate and to be activated in the adrenal
ZF in mice [31], again suggesting the adrenal
cortex to be predisposed for the influence of at least some EDCs in vivo.
The fine-tuned functionality of cytochrome P450 (CYP) enzymes in the adrenal gland
carries the potential to metabolise and further activate exogenous substances,
potentially aggravating their local toxicity. For instance, DDT-metabolites were
covalently bound to proteins and water-soluble derivates were formed in vitro, which
was inhibited by CYP-inhibiting metyrapone [31]. Besides, the adrenal’s susceptibility for oxidative
stress-induced lipid peroxidation is generally elevated due to the abundance of
polyunsaturated fatty acids in adrenal lipid membranes.
Importantly, the adrenal gland is an important player in endocrine circuits, like the
hypothalamic-pituitary-adrenal axis (HPA) or the renin-angiotensin-aldosterone
system (RAAS). Therefore, disruption of endocrine processes in the brain or the
kidney might affect adrenal homeostasis as well. Last but not least, EDCs might
target multiple extra-adrenal systems involved in steroid distribution or peripheral
hormone action, for example, by competitive binding of hormone carrier proteins,
(ant-)agonism at target receptors, and peripheral (de-)activating of enzymes [27]
[32].
Key characteristics for the determination of endocrine-disruptive properties of
chemicals were identified in a consensus statement for improved hazard
identification [33]:
-
(ant-)agonism at cellular receptors
-
alteration of receptor expression
-
interference with intracellular signalling pathways
-
interaction with nucleic acids via epigenetic modifications
-
alteration of hormone synthesis, secretion, and distribution
-
effects on proliferation, differentiation, or migration
-
interference with cell fate and tissue organisation
-
effects on peripheral enzyme and receptor expression [34],
-
disruption of circadian rhythmicity in hormone secretion and gene expression
[35],
-
induction of oxidative stress [36]
[37]
Common endocrine disrupting chemicals, their primary application, and experimental
outcomes regarding the adrenal cortex are listed in [Table 1].
Table 1 Common endocrine disrupting chemicals, their primary
application, and experimental outcomes regarding the adrenal cortex.
Arrows indicate increasing or decreasing effects. Formulas were drawn
with PubChemSketcher V2.4.
Endocrine-disrupting chemicals
|
Structure
|
Application
|
Exemplary outcomes [Ref]
|
Bisphenols
|
Bisphenol A (BPA), Bisphenol F (BPF)
|
BPA
|
Plasticizers in polycarbonate plastics, epoxy and vinyl resins;
found in plastic bottles, baby bottles, thermal and currency
paper, coatings in drinks and food cans
|
Estrogen, gluco-/mineralocorticoid, progestogen, androgen
activity [39]
[40]
[41]
[42]; disrupted gene
expression of StAR [58],
CYP, HSD [63]
[64]; ↓ antioxidant
defence, ↑ ROS [36]; ↑ serum glucocorticoids (GC) [74]
[75]; ↓ GR
expression [75]; vascular
congestion [36]; ↑
ZF thickness, ↓ ZR thickness [75]; less robust coping to
stressors, sex-dependent neurobehavioral alterations (anxiety,
depression-like phenotype) [73]
[74]
|
Phthalates
|
Diethlyhexyl- phthalate (DEHP), Dibutyl-phthalate (DBP)
|
DEHP
|
Plasticizers in polyvinyl chloride polymers (PVC); found in
wires, plastic bottles, medical equipment, lacquers, varnishes,
paints, fixatives in perfumes, insect repellents
|
Androgen, glucocorticoid, progestogen activity [43]; PPARγ affinity
[46]; disrupted
expression of potassium channels [49], AGTR1a/b,
LDL-R [50]; differentially
activated transcription factors [54]; ↑ DNA methylation [44]; cholesterol synthesis
[50]; disrupted
expression of StAR, CYP, HSD [60]
[61]
[62]; CYP-inhibiting effects
[65]; binding of CBG,
SHBG [77]
[78], human serum albumin
[81]; ↑ ROS,
gene and protein oxidation [60]; lipid accumulation [50]; ↑ cytokines
[84]; angiectasis
[84]; ↓RAAS
signalling [93]
|
Poly-brominated diethyl ethers (PBDE)
|
4-Bromodiphenyl ether (BDE-3),
2,2′-4,4′-Tetrabromo-diphenyl ether (BDE-47)
|
BDE-47
|
Flame-retardant substances; found in furniture, textiles,
vehicles, plastics
|
↑ Cortisol, ↑ aldosterone, ↑ serum GC
[59]; disrupted gene
expression of StAR, CYP, HSD [51]
[59], SF-1
[51]; altered
cholesterol uptake, intracellular signalling [51]; selective adrenal
weight gain [59];
accumulation in the adrenal cortex [29]
[30]
|
Poly-chlorinated biphenyls (PCB)
|
PCB126, PCB153
|
PCB153
|
Plasticizers, additives in PVC polymers, pigments in ink;
industrial use as insulating fluids, for transformers,
capacitors; hydraulic and lubricating fluids
|
↑ 17-OH-pregnenolone, ↑ DHEA; ↓
estradiol, ↓ corticosterone; disrupted gene expression
of StAR, CYP, HSD [48];
elevated levels in aldosterone-producing adenoma [26]
|
Per- and poly-fluoroalkyl substances (PFAS)
|
Perfluoro-octane- sulfonic acid (PFOS)
|
PFOS
|
Water-repellent textiles and paper products; fire-fighting foams,
skiing wax, cosmetics, impregnation agents
|
Disrupted gene expression of StAR, CYP, HSD, MC2R ; ↑
17-OH-pregnenolone, ↑ DHEA; ↓ cortisol,
↓ corticosterone, ↓ aldosterone [48]; ↓ serum GC,
↓ ACTH, ↓ CRH [70]; ↑ serum CBG [80]; ↓ central
expression of CRHR, GR [70]
|
Alkylphenols
|
Octylphenol (OP), Nonylphenol (NP)
|
OP
|
Detergents, additives in fuels, lubricants; found in fragrances,
tires, adhesives, coatings, carbonless copy paper, rubber
products
|
↑ Serum GC, ↑ ACTH, ↑ CRH; hyperplasia,
↑ vascularisation, macrophage infiltration [72]
|
Organo-chlorides
|
Hexachlorohexane/-benzene (HCH/HCB)
|
HCB
|
Agricultural pesticides, former pharmaceutical use (lindane)
|
DHEA ↑ [48];
elevated levels in aldosterone-producing adenoma [26]
|
|
Dichlorodiphenyltri-chloroethane (DDT)
|
DDT
|
Agricultural insecticide, former pharmaceutical use (malaria,
typhus, leishmaniasis), mitotane (= DDT-derivate)
|
Developmental retardation and dysmorphic growth [85]
[86]; accumulated in adrenal
cortex [31];
metabolization by adrenal CYP enzymes [31]
|
Organotins
|
Tributyltin (TBT)
|
TBT
|
Biocidal anti-fouling paint in ships, vessels; disinfectants,
fertilizer, wood/textile production, stabilizer in PVC;
found in textiles, plastic polymers, seafood
|
↑ 17-OH-pregnenolone, ↑ progesterone, ↑
DHEA, ↑ 11-deoxycorticosterone, ↓ corticosterone
[48]; ↑ serum
GC, ↓ ACTH [71];
hyperplasia [71], cellular
hypertrophy ZG, ZF; loss of architecture [69]; lipid accumulation,
mononuclear, neutrophil, mast cell infiltration; apoptosis
induction fibrosis [71]
|
Agonism/Antagonism at receptors
Agonism/Antagonism at receptors
EDCs act as exogenous ligands at nuclear receptors. In steroid-producing cells, these
include estrogen (ERα/β), androgen (AR), glucocorticoid
(GR), mineralocorticoid (MR), and progesterone (PR) receptors. EDCs’ effect
on nuclear receptors is mediated by direct binding, impairment of nuclear
translocation, binding to hormone-responsive elements or via changes in receptor
expression [38].
For instance, BPA’s affinity to ERs and its estrogenic effects have been
reported already in 1936. Further, next-generation bisphenols show similar actions
at ERs. Meanwhile, computational analyses identified distinct binding sites of
bisphenols on several steroid receptors [39],
while receptor activation was confirmed by reporter gene assays in vitro [40]
[41]
[42].
Some high-weight phthalates show higher affinity to AR, PR, and GR than endogenous
ligands [43] and might thereby mediate their
action on the adrenal gland in vivo [44]. For
instance, DEHP and monoisodecyl phthalate (MIDP) showed stronger binding to GR than
the natural ligand cortisol in silico [43].
The fungicide atrazine has been shown to interact with steroidogenic-factor 1
(SF-1/NR5A1), a nuclear receptor regulating steroidogenic pathways, followed
by an activated signalling and enhanced transcription of steroidogenic enzymes in
vitro [45]. Peroxisome proliferator agonist
receptor (PPAR) subtypes serve as regulators of genes involved in lipid metabolism
or inflammatory processes in the adrenal cortex. For instance, substances, that are
introduced as alternatives to hazardous phthalates, such as DINCH, bind and activate
PPARγ. Parallel lipid accumulation and provoked oxidative stress in
adipocytes is suggested to be partly mediated by this receptor interaction [46].
Zhang et al. mapped the endocrine activity of contaminated soil samples on
steroid-dependent nuclear receptors, such as AR, MR, or GR. Most samples contained
receptor-binding compounds, such as DDT, and other chlorinated contaminants
underlining the problem of pollution with endocrine active substances [47].
Receptor expression
Modifying receptor expression in the adrenal gland and responsiveness to
physiological stimuli, especially adrenocorticotropic hormone (ACTH), angiotensin II
(AngII), or potassium, represents another potential target of EDCs. Physiological
ligand-receptor interactions and subsequent signalling may be affected by
dysregulated receptor density. The melanocortin receptor 2 (MCR2), responsible for
ACTH signalling in the ZG and ZF, is altered by perfluorinated octanoic acid (PFOS)
and PCB126 on the mRNA level [48].
Transcriptomic analyses following prenatal diethylhexyl phthalate (DEHP) treatment
of rats revealed altered gene expression of potassium channels and AngII receptors:
KCNK5 expression was upregulated [49], whereas
the angiotensin II receptors AGTR1a/b were downregulated, followed by
altered aldosterone secretion [50]. SF-1
expression was shown to be enhanced by 4-bromodiphenyl ether (BDE-3) in vivo [51]. Moreover, alterations of receptor activity
involved in cholesterol metabolism have been shown to be affected by EDCs. While the
low-density lipoprotein (LDL) receptor was enhanced by DEHP [50], the preferred pathway for cholesterol
uptake via SR-B1 was upregulated by BDE-3 [51].
Intracellular signalling pathways
Intracellular signalling pathways
Pathways mediating essential intracellular cascades can be affected by EDCs. There is
sufficient evidence that biochemical activation, that is, via phosphorylation, and
translocation of signalling proteins, second messengers or transcription factors are
disrupted in their precise function in the cell’s adaptation to stimuli.
In mice treated with flame-retardant BDE-3, disrupted phosphorylation patterns of
transcription factors, such as cAMP response element-binding protein (CREB), and
enzymes, like AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinases
(JNK), have been shown. Thus, BDE-3-deactivated AMPK and CREB could affect enzyme
levels via modification of transcription [51].
BPA has been found to induce JNK phosphorylation, associated with elevated CYP11A1
activity and corticosterone production in adrenal cells and in vivo [52]. In addition, the expression of
transcription factors, such as sonic hedgehog (Shh) and its nuclear translocation to
binding sites, might be impaired by BPA-bound ERβ. This resulted in
increased cyclin D transcription and a potentially disrupted cell cycle [53].
Whole-genome sequencing following prenatal DEHP exposure of rats revealed
dysregulated genes of transcription factors (CREB, CREM, NR4A1, NR4A3), PPAR and
MAPK (mitogen-activated protein kinase) pathways. In adult rats, the susceptibility
for further hits targeting similar pathways, for instance PPAR-antagonists, was
enhanced [54].
Epigenetic changes
Endocrine disruptors can interfere with the human epigenome via changes in DNA
methylation, histone modification and expression of aberrant microRNAs (miRNA) [55]. These alterations by EDCs are ultimately
passed on to the offspring via multi- or transgenerational inheritance [24]
[56].
DNA methylation levels of nearly two million CpG dinucleotides were assessed after in
utero exposure of rat adrenal glands to DEHP, and 972 differentially methylated CpGs
were identified. Alterations in gene expression of specific adrenocortical genes,
such as angiotensin receptors, potassium channels or steroidogenic enzymes, could
only partially be explained by epigenetic changes, as no significant epigenetic
modifications were found in their promoter region. However, differentially
methylated CpG clusters were associated with gene loci programming for immune
response, cell cycle and growth and tissue development. It was hypothesised that
DEHP might activate the nuclear receptors PPARα and PPARβ, thereby
inducing epigenetic modifications manifested in altered gene expression and steroid
secretion [44]. However, specific epigenetic
changes in the adrenal development and function are rarely investigated.
Steroidogenic enzyme expression
Steroidogenic enzyme expression
Activity and expression of steroidogenic enzymes can be affected by EDCs as backlog
effects, or altered metabolization of precursor hormones might imbalance
steroidogenic capacity. mRNA levels of enzymes responsible for endogenous
cholesterol synthesis and conversion (HMG-CoA-reductase and -synthase) were
upregulated following prenatal DEHP exposure, promoting cholesterol production [50]. Transcriptional regulation of
mitochondrial steroidogenic acute regulatory protein (StAR) was profoundly altered
by treatment with glyphosate over 14 days in adult male rats. Reduced proteinkinase
A (PKA) activity led to hypophosphorylation of CREB and StAR itself promoting
impaired function and transcription of StAR [57]. Meanwhile, BPA increased protein levels of StAR dose-dependently in
H295A cells. This effect might be ER-mediated [58].
Transcription and translation of subsequent steroidogenic enzymes, for example,
CYP11, CYP17, CYP19, CYP21, HSD3B2, and HSD17B1 have been shown to be altered by
PBDEs [51]
[59], phthalates [60]
[61]
[62],
bisphenols [63]
[64], PFAS, or PCBs [48]. In silico analyses demonstrated direct
inhibitory effects of phthalates on CYP450 enzymes involved in steroidogenesis via
molecular docking. Some phthalate metabolites show even stronger affinity to CYP19A1
or CYP11B1 than therapeutical CYP-inhibitors, for example, exemestane or metyrapone
[65]. Phthalates, alkylphenols and
bisphenols show direct inhibition of sulfotransferase SULT2A1, which catalyses the
sulfonation of DHEA to DHEAS, detectable by accumulating radio-labelled substrate
PAPS (3′-phosphoadenosine-5′-phosphosulfate) in vitro [66].
The peripheral action of adrenal glucocorticoids is regulated by hydroxysteroid
dehydrogenases (HSD). HSD11B1/2 catalyse the conversion of active cortisol
to cortisone and vice versa. In vitro, EDCs can interact with HSD11B1/2
followed by altered expression and activity in multiple target tissues of
glucocorticoids [34]. For instance, TBT alters
HSD11B2 expression and enzymatic activity in placental cells and thereby enhances
cortisol deactivation [67].
Hormone synthesis and secretion
Hormone synthesis and secretion
The steroidogenic enzyme cascade itself poses another potential target for EDCs.
Alteration of steroid levels due to disrupted enzymatic activity affects the
physiological role of steroids in vivo and in vitro.
A significant number of studies make use of the adrenocortical carcinoma-derived
NCI-H295R cells as an established model for human steroidogenesis. H295R cells were
treated with different EDCs measuring alterations in steroid levels and gene
expression: enhanced secretion of effector hormones, such as aldosterone or
testosterone were observed, whereas precursor hormones, such as
17-hydroxyprogesterone, pregnenolone, or 11-deoxycorticosterone, were decreased.
Most pronounced effects were observed following 48 hours of exposure to
TCDD, PCB 126/153, tributyltin (TBT), and
2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) [48]. Importantly, effects of BDE-47-treatment
on aldosterone and cortisol secretion suggest a time- and dose-dependent effect on
steroidogenic pathways. Some EDC-driven effects appear to take at least
72 hours to overcome a “transcriptional and translational
delay”. The effects could be observed under stimulated and unstimulated
conditions [59].
Additive effects of combinatory EDC treatment are hypothesised to be relevant for
adverse outcomes in vivo, as realistic exposure is not limited to single compounds.
Furthermore, combined toxicity has been suggested to aggravate effects of EDCs by
synergistic or additive effects [48]
[68]. Combination of EDCs, such as TCDD, PCBs,
PFOS, TBT, and BDE-47, which had no effect in single use, was shown to exert
relevant additive effects on steroidogenesis, for example, a decrease of DHEA [48]. Mixtures of chlorinated, brominated, and
perfluorinated substances were tested in different constellations in H295R cells for
48 hours. Most pronounced effects on glucocorticoids were found for mixtures
of brominated and perfluorinated compounds – however, in levels 10 000 times
higher than measured in human serum [68].
Most in vivo studies investigating endocrine disruption focus on effects on
glucocorticoid levels. Suppression (e. g., in the presence of tributyltin,
PFOS) [69]
[70]
[71] or elevation
(e. g., in the presence of BDE-47, octyl-/nonylphenol, BPA) [36]
[59]
[72]
[73]
[74]
[75] of corticosterone levels
was induced by a significant number of administered endocrine disruptors in animals.
For instance, rats treated with PFOS (0.5 to 6.0 mg/kg body weight
for 28 days) showed reduced corticosterone levels [70], whereas in utero BPA-exposed female rats had elevated basal
corticosterone [76]. However, interspecies
differences complicate a clear statement on the role of adrenal androgens, as rats
lack CYP17 in adrenal tissue [32]. Certainly,
systematic steroidobolomic studies at environmentally relevant concentrations and
combined toxicity analyses are needed to ensure realistic conditions.
Hormone distribution
Secreted corticosteroids are distributed via the bloodstream and mainly bound to
transport proteins. This ensures solubility and availability at target tissues,
while metabolic degradation is attenuated. Glucocorticoids bind to
corticosteroid-binding globulin (CBG), androgens and estrogens bind to sex
hormone-binding globulin (SHBG), whereas for instance aldosterone, progesterone or
DHEAS predominantly bind to serum albumin. Phthalates are able to bind to CBG and
SHBG in silico with similar affinity as cortisol or dihydrotestosterone, the natural
ligands [77]
[78]. Hang et al. reported binding of several substances, e. g.
phthalates, parabens, and benzophenones, to SHBG [79]. Enhanced serum CBG was detected in mice following oral PFOA exposure
for 28 days [80]. Besides, different
phthalates [81], BPA [82] or its substitute BPF [83] have been shown to bind to human serum
albumin, additionally provoking confirmational changes of the protein structure,
thereby potentially altering unbound fractions of steroids in the bloodstream.
Oxidative stress
Maintenance of redox balance due to extensive lipid metabolism and production of
reactive oxygen species (ROS) during steroidogenic reactions appears to be an
essential part of the adrenal metabolism. Exogenous disruptors, which promote ROS
generation or impair antioxidant mechanisms, might imbalance a precise homeostasis.
As cytochrome P450 enzymes conduct hydroxylation reactions and thereby produce free
radicals, steroidogenesis is prone to ROS accumulation. Redox status in the adrenal
gland is maintained via non-enzymatic, that is, via ascorbic acid (which shows
highest concentration in the adrenal cortex), and enzymatic systems, for instance
glutathione peroxidase or thioredoxin. Several EDCs, like bisphenols, phthalates, or
parabens are known to contribute to ROS generation, and might additionally reduce
the activity of antioxidant enzymes [37]. In
an animal experiment, lowered activity of antioxidant enzymes and reduced
glutathione (GSH) were detected following BPA (10 mg/kg body weight
for 14 days) treatment in rats. Here, BPA-induced ROS provoked lipid peroxidation,
quantified as malondialdehyde amount. Additionally, elevated corticosterone and ACTH
levels were reported, as well as ZF hyperplasia. All observed effects were
attenuated by concomitant treatment with antioxidant melatonin [36]. In H295R cell culture, superoxide gene and
protein oxidation were induced in the presence of di-/monobutyl phthalate
(DBP/MBP), while gene expression of essential CYP enzymes was decreased.
Consequently, DBP treatment led to lowered androgen and corticosterone secretion
[60].
Tissue homeostasis
The highly specific adrenal tissue organization allows the complex functions of the
adrenal cortex in vivo. Therefore, disrupted cell differentiation and intercellular
interaction might influence adrenal functionality.
Several histological studies report zone-specific hyperplasia of adrenocortical cells
following EDC treatment [69]
[71]
[72]
[75]. Treatment of adult rats
with TBT resulted in hyperplasia of the pituitary and adrenal gland [71] with consecutive diffuse cellular
hypertrophy, especially in ZG and ZF [69].
Similarly, lizards treated with octyl- and nonylphenol showed strong hypertrophy of
steroidogenic cells and enhanced vascularization, concurrent with elevated ACTH
which might have mediated adrenal growth [72].
Thickened ZF was detected in offspring of BPA-treated rats
(40 μg/kg body weight/day), while reduced thickness
and dysmorphic architecture of the ZR were detected [75]. Zone-specific hypo- or hyperplasia suggests distinct involvement of
adrenocortical cell subpopulations in the toxic effects of EDCs.
Several in vivo studies report specific changes in adrenal weight, while other organs
remain unaffected. For instance, relative adrenal weight was observed to be reduced
at high doses of DBP (500–1000 mg/kg body weight/day
for 14 days) and DEHP (750–1500 mg/kg body
weight/day for 14 days) treated rats [84], whereas chronic exposure to BDE-47
(10–100 μg/kg body weight/day for 16 weeks)
resulted in increased adrenal, but not in heart, liver or kidney weights [59].
Interestingly, effects on adrenal gland morphology seem to be sex-dependent. For
instance, perinatally BPA-exposed female rats presented higher adrenal weights
compared to their male littermates. While hyperplastic zona fasciculata could be
detected in both sexes, the zona reticularis was specifically reduced or missing in
male rats. Accordingly, hormone levels, receptor expression, and behavioural coping
was found to be altered in a sex-dependent manner [75].
Histological studies revealed increased cytoplasmic accumulation of cholesterol and
precursor hormones in the adrenal cortex [50]
[69]
[71]. Female rats treated with 100 ng
TBT/kg body weight/day for 15 or 30 days resulted in an intense
lipid accumulation [71]. Similarly, maternal
exposure to DEHP (1–300 mg/kg body weight/day from
GD14 until birth) resulted in a dose-dependent increase of lipid droplets in the
adrenal glands of the offspring. Concurrently, LDLR and HMGCR expression was
upregulated promoting increased lipid input and de novo cholesterol synthesis [50]. TBT might inhibit the transformation of
cholesterol to steroids (early blockade of steroidogenesis), whereas DEHP might
promote uptake and deposition of lipids in the adrenal cell.
In terms of tissue development, pathways involved in intercellular contacts, zone
formation, proliferation and differentiation were shown to be inhibited by pre- and
perinatal DDT-treatment (pregnant rats received 2–3 μg
DDT/kg body weight/day). Developmental retardation in the ZR has
been observed in the presence of insecticidal DDT: Immunohistochemical analyses
showed reduced nuclear and elevated cytoplasmic fractions of β-catenin
suggesting an insufficient activation of β-catenin/Wnt-signalling in
the ZR [85]. The Wnt-pathway plays an
important role in formation of tissue patterns, proliferation and differentiation
[86]. Furthermore, Oct4 expression and
Ki67-index were lowered in the ZR. Oct4+ cells form a cell pool involved in
pluripotency and tissue homeostasis. Therefore, DDT surrogatively impairs the
development of in utero exposed rats by downregulating essential pathways and
consequently diminished cell proliferation and tissue repair [85]. Overall, the presence of DDT in the
developing adrenal cortex resulted in dysmorphogenic alterations and retarded
growth. Nonetheless, DDT is claimed for its adrenocorticolytic effects which led to
the therapeutic use of its derivate mitotane in treatment of adrenocortical
carcinoma (ACC) [87].
The chronic exposure to TBT caused loss of arcade patterns in the adrenal cortex and
a random disposal of cells in male rats. Effects became more pronounced over time
[69]. Similar histological lesions became
apparent after DBP (100–1000 mg/kg body weight/day)
or DEHP (250–1500 mg/kg body weight/day) exposure to
male rats. A loss of adrenal architecture and degeneration of cells was described,
as well as cellular congestion and loss of cell granularity [84].
Furthermore, local inflammation appears to be associated with chronic exposure to
some endocrine disruptive agents. Several in vivo studies report immune cell
infiltration in EDC-treated adrenal glands. TBT was shown to increase mononuclear
and neutrophil cell counts in adrenal cortices of female rats alongside with an
increased activity of macrophagous NAG
(N-acetyl-β-d-glucosaminidase) and neutrophil MPO
(myeloperoxidase). Besides, the number of mast cells was increased. Local
inflammation concomitantly occurred in the pituitary gland [71]. Meanwhile, severe macrophage infiltration
became evident after octyl- and nonylphenol treatment in adrenal tissue of lizards
[72]. Furthermore, enhanced apoptotic
markers, such as caspase-3 expression, suggest the induction of intrinsic apoptosis
in the chronic presence of TBT. Thereby, elevated collagen deposition (fibrosis) in
the adrenal cortex might be the consequence of replacing tissue defects induced by
TBT [71]. Moreover, acellular immune
regulation might be induced by the presence of DBP and DEHP in male rats. Serum
levels of the proinflammatory IL-1 and TNFα were increased after 14 days of
treatment. By alternating steroidogenic gene expression and reducing glucocorticoids
levels, phthalates might exert cascadic effects on the adrenal gland and systemic
immune balance as glucocorticoids can directly regulate a proinflammatory status
[84].
Adequate vascular organisation in the adrenal cortex is required to maintain supply
and transport of essential metabolites. Alkylphenols have been associated with
enhanced vascularisation in adrenal tissue of lizards [72]. Meanwhile, dose-dependent angiectasis has
been observed in the adrenal cortex of DBP/DEHP treated rats impairing
efficient blood supply [84]. Reduced
immunostaining of contractile and cytoskeletal elements of blood vessels was
observed in adrenal glands of BPA-exposed rats. This likely results in reduced
vascular contraction and congestion and disrupted integrity of adrenal vessels [36].
Disruption of endocrine circuits
Disruption of endocrine circuits
Many in vivo studies investigating HPA-disruption report dissociated hormone levels
of hypothalamic corticotropin releasing hormone (CRH), adrenocorticotropic hormone
(ACTH) and adrenal corticosterone: while BPA (10 mg/kg body
weight/day for 14 days) enhanced glucocorticoid, ACTH, and CRH levels in the
serum of treated rats [36], as well as their
perinatally exposed offspring [73]
[74], PFOS (0.5–6 mg/kg
body weight/day for 28 days) suppressed levels of all three hormones [70]. Treatment with low-dose TBT
(100 ng/kg body weight/day for 15, or 30 days,
respectively), revealed elevated levels of corticosterone, while serum ACTH was
suppressed [71].
The short-term exposure to ambient particulate matter (PM2.5) as a
ubiquitous environmental factor resulted in an activated HPA and therefore enhanced
ACTH and glucocorticoids in an experimental [12], as well as in an epidemiological setting [88]. Particulate matter acts as an
environmental transport medium of various chemical compounds, such as inorganic ions
(nitric oxides, sulfur oxides), organic carbons, and heavy metals. Known endocrine
disruptive substances may be included, for example, polycyclic aromatic hydrocarbons
(PAH), or phthalates [89]. Exposed rats
(average exposure of 62.6 μg/m3) showed elevation
of CRH, ACTH and cortisol levels, as well as an increased cytokine expression (IL-6,
TNFα) in the hypothalamus, pituitary, and adrenal gland [12]. Accordingly, a randomized-controlled trial
investigating effects of air purification detected enhanced levels of cortisol and
cortisone associated with higher exposure to PM2.5 (average personal
exposure of 53.1 μg/m3) [88].
To maintain glucocorticoid homeostasis in target tissues, hormone receptor levels
appear to negatively correlate with steroid levels. Consequently, a downregulation
of GR in the hypothalamus of female rats has been observed at elevated
corticosterone levels in the presence of BPA (40 μg/kg body
weight throughout pregnancy and lactation). This resulted in limited responsiveness
to glucocorticoid feedback [75]. A 28-day
treatment of rats with PFOS decreased levels of CRH, ACTH and corticosterone at all
administered concentrations from 0.5–6 mg/kg body
weight. Consequently, expression of CRH receptor (CRHR) and GR were
dysregulated in the limbic system, hypothalamic PVN, pituitary, and adrenal gland
[70]. Moreover, a mixture of phthalates,
pesticides and BPA have been shown to induce hypomethylation and altered
transcription of hippocampal HPA-related genes: MR and CRHR [76]
[90],
as well as hippocampal and hypothalamic FKBP1, an important regulator of
glucocorticoid receptor expression in the brain [91].
Behavioural studies in rodents following exposure to EDCs have shown sex-dependent
alterations of HPA physiology and associated behaviour [74]
[75].
Pregnant rats orally administered with BPA 40 μg/kg body
weight/day throughout pregnancy and lactation resulted in disruption of
hormone secretion and hippocampal GR deficiency in the offspring. Behavioural
testing, such as the forced swim test, revealed a less robust coping to stressors,
suggesting anxiety and a depression-like phenotype [75]. Perinatally BPA-exposed male rats (subcutaneous injections of
2 μg/kg body weight in dams) similarly showed
depression-like behaviour. Contrary behaviour was seen in females, which presented
which lower post-stress levels of corticosterone and ACTH and reduced anxiety-like
behaviour in behavioural testing [74]. By
targeting basal and stress-reactive HPA activity, EDC exposure might be associated
with the development of stress-related disorders [75].
The RAAS addresses the adrenal ZG in systemic blood pressure control and salt
balance. Disturbed feedback mechanisms in renin, angiotensin and aldosterone
signalling might lead to hypertension or hypokalaemia. In vivo studies have found
disrupted angiotensin II and renin expression in kidney tissues following maternal
exposure to DEHP (0.25–6.25 mg/kg body weight) in rat
offspring [92], suggesting the RAAS to be an
additional target of EDC’s action. Reduced systemic arterial blood pressure
associated with reduced aldosterone levels was shown in the offspring of perinatally
DEHP-exposed rats [93].
Discussion
Humans are exposed to a complex mixture of EDCs in low doses. These EDCs can
accumulate in lipophilic tissues and tend to alter endocrine pathways and
homeostasis. As discussed, the adrenal cortex represents a common toxicological
target. Yet, the mechanisms of adrenocortical and HPA disruption and their
involvement in adverse outcomes remain incompletely understood. Subsequently,
challenges and gaps in EDC research targeting the adrenal system will be
discussed.
A schematic overview of discussed potential targets for endocrine disruption in the
adrenal cortex is shown in [Fig. 1].
Fig. 1 Schematic overview of discussed potential targets for endocrine
disruption in the adrenal cortex. EDCs can interfere with the adrenocortical
system at several points. a : A superior system, such as the
hypothalamus or pituitary gland, regulates glucocorticoid synthesis via the
corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone
(ACTH). b : Similarly, aldosterone secretion is stimulated by the RAAS
system by angiotensin II (AngII). c : External stimuli mediate their
action via own receptors, such as the melanocortin 2 receptor (MC2R), the
angiotensin II receptor (AGTR) or potassium channels (KCNK). d : The
glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone
receptor (PR), peroxisome-proliferator-agonist receptor (PPAR) or
steroidogenic factor 1 (SF-1) are essential for intracellular signalling of
steroids on a transcriptional level (e ). f : Via epigenetic
modifications transcription of key genes is modulated. g : Signal
proteins, such as CREB and their phosphorylation status mediate
intracellular pathways. h : Cholesterol, as precursor of
corticosteroids, is either uptaken by low-density lipoprotein receptor
(LDL-R) or by scavenger receptor B1 (SRB1). i : De-novo synthesis is
conducted by HMG-CoA-reductase. j : Corticosteroids are synthesized in
the mitochondria and the smooth endoplasmatic reticulum mediated by steroid
acute regulatory protein (StAR) cytochrome P450 enzymes (e. g.,
CYP21A2) and hydroxysteroid dehydrogenases (HSD). k : Steroids are
bound to proteins, such as corticosterone binding protein (CBG). l :
In their target tissues, steroids bind their nuclear receptor, activate
hormone signalling pathways and are eventually inactivated. m :
Steroidogenic reactions afford precise redox balance in the adrenocortical
cell. Created with biorender.com. [rerif]
Dose
Levels of endocrine disruptive agents detected in serum or urine are usually in the
nano- to low micromolar range, posing a chronic, but low-dosed exposure. Most
studies indicated dose-dependent effects on steroidogenesis and further endpoints.
However, most studies report adverse outcomes at unrealistic concentrations. The
extrapolation of detected effects to realistic doses is certainly difficult to
fulfil since EDC concentrations are rarely quantified in the adrenal tissue.
Retrospective biomonitoring data are fundamental approaches to asses realistic EDC
burden [25]. However, monitored exposure
levels vary due to population, location, and occupation. For instance, reported
serum BPA ranged from about 10 μM in exposed workers to nanomolar
concentrations in the general population [63].
With respect to the adrenal cortex, accumulative and depositing effects are
difficult to quantify and need to be considered in the future hazard identification
of EDCs.
Time
The complexity of a chronic exposure to toxicants poses another intricacy in the
study of adrenocortical disruption. Long-term studies are needed to detect pre- and
postnatal effects of environmentally relevant concentrations of endocrine disruptors
in vivo. Lifelong contact to endocrine disruptors raises the question how to
transfer the model of a chronic exposure of human cells to laboratory assays.
Furthermore, the time of exposure in life significantly contributes to the
vulnerability to EDC-driven effects. Foetal development and differentiation, which
are intimately regulated by hormones, might be impaired by an unfavourable
environment in utero. Preliminary data suggest that in utero exposure may have
effects on organogenesis and tissue organization of adrenal glands in animals [85]
[86].
However, the implications on human development and pathogenesis are unclear.
Combinatory effects
Studies on combined toxicity of EDCs often lack a standardised approach. Sometimes
equimolar concentrations are applied, whereas in other studies mixtures adjusted to
environmental concentrations are used to screen for disruptive effects [48]. For a better understanding of
EDCs’ impact on the adrenocortical system, studies using doses equivalent to
levels found in vivo are urgently needed.
Common screening methods
Effects on steroidogenesis are often analysed using the NCI-H295R cell line, which
has emerged as a screening tool for adrenocortical physiology and potential
endocrine disruption [94]
[95]
[96].
This is already implemented in the screening panel for the hazard identification of
newly developed chemicals, proposed by the OECD and the US-EPA. However, the
established “steroidogenesis assay“ is limited to an exposure of
48 hours and the detection of altered testosterone and estradiol levels in
supernatant [97]. Clinically relevant gluco-
and mineralocorticoids and the role of adrenal androgens, such as DHEAS have been
ignored in many previous in vitro studies. Similarly, in vivo studies lack the
detection of overall steroidogenesis disruption. A reliable, standardised, and
straightforward approach detecting overall adrenal steroidogenesis is needed for
thorough screening of endocrine disruption – desirably ahead authorisation
of novel substances.
Circadian rhythmicity
Circadian steroid secretion has been rarely considered in environmental
endocrinology. Secretion of glucocorticoids follows a circadian rhythmicity, which
seems to be regulated by a finely tuned interplay of various mechanisms. Pulsatile
secretion of hormones in hypothalamic nuclei and intrinsic oscillatory gene
expression regulate the circadian rhythm in glucocorticoid secretion. Parallel
endocrine and circadian disruption have been revealed in certain
hypothalamic-pituitary axes, while at the same time clear mechanistic evidence of
circadian disruption in adrenocortical cells and the HPA axis is lacking. How and if
endocrine disruptors may influence diurnal glucocorticoid patterns has not yet been
investigated [35], although relevant
components of adrenal rhythmicity, for example, StAR [98], are known as targets of certain EDCs.
Epigenetics and DOHaD
Furthermore, epigenetic effects of EDCs via DNA methylation or histone modifications
have been rarely considered in the adrenal cortex. However, by passing epigenetic
alterations to progenies via trans- and multigenerational inheritance, EDCs become a
potential risk factor in developing organisms. Endocrine disruptors as a part of the
developmental origins of health and diseases (DOHaD) reinforce our current
responsibility for the health of future generations [24].
Adrenal-related disorders
Adrenal-related disorders
Another central lack of knowledge is the potential clinical outcomes in the adrenal
system induced or mediated by EDC exposure. The links between the exposome and
steroid-related disorders are limited to association studies. However, EDCs were
shown to alter levels and activity of the HPA axis, concomitant with central
receptor expression, abundance, and distribution in the brain, affecting central
responsiveness to glucocorticoids. Meanwhile, dysregulated HPA axis is observable in
various disorders like depression, anxiety, metabolic dysfunction, obesity, and
post-traumatic stress disorder. An inadequate reaction to altered environmental
demands might result in a cascade of pathological events promoting pathogenetic
processes [99]. Importantly, phases of pre-
and early postnatal development mark the most vulnerable time window for an aberrant
HPA programming by environmental factors [75].
Although enhanced levels of EDCs have been detected in patients with anxiety or
depression [8], the mediation by an
EDC-disrupted adrenal system in pathogenesis of stress-dependent mental disorders
remains speculative.
Only a limited number of clinical trials investigated the association between the
exposome and the prevalence of adrenal neoplasia in humans. While BPA serum levels
were elevated in patients suffering from non-functional adrenocortical incidentaloma
[25], PCB and organochloride
concentrations in the adrenal cortex of patients with aldosterone-producing adenoma
were significantly increased [26]. Both
studies suffer from a small sample size and the unclear causality between individual
exposure and disease incidence. However, 80% of EDCs are described as
potentially tumorigenic promoting neoplasia in other steroidogenic tissue, such as
ovaries, or testis. Among them, phthalates, heavy metals, and particulate matter
were most often associated with endocrine neoplasia [100].
Meanwhile, polycystic ovary syndrome (PCOS), predominantly accompanied by
hyperandrogenaemia, is a multifactorial disorder of the female reproduction tract.
Epidemiological studies reported significantly elevated serum BPA levels PCOS
patients, which correlated with enhanced androgen levels [101]
. However, 20–30% of
PCOS patients demonstrate an excess of adrenal precursor androgens, such as
dehydroepiandrosterone (sulfate), potentially linking altered adrenal steroid
production to reproductive disorders [102].
Conclusion
In this review, we have discussed the evidence on various targets and disruptive
mechanisms of known EDCs within the adrenocortical system. Despite limitations,
which we acknowledge, there is an increasing body of evidence that supports
associations between the exposure to certain endocrine disruptive agents and adverse
outcomes in the adrenal system. In conclusion, the adrenal cortex, its associated
hormones, and their implication in the organism is indeed affected by the exposome.
However, causal ascriptions of endocrine disruptive activity and the pathogenesis of
steroid-related disorders, such as neurobehavioral disorders or endocrine neoplasia,
remains unclear and requires further investigation. The abundance and extensive
distribution of hazardous chemicals and developing evidence on their adverse health
effects raises concern and emphasises the need to extend research of these EDCs.